Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.

ABSTRACT:

Introduction

Treatment intensification beyond androgen deprivation therapy (ADT) has shown survival benefit in patients with metastatic castration-sensitive prostate cancer (mCSPC). There is a need to better understand how these novel treatments fit in real-world practice.

Methods

Using electronic medical records and administrative data, a population-based, retrospective cohort study of patients diagnosed with de novo mCSPC between 2010 and 2020 in Alberta, Canada, and initiated on ADT was conducted. Treatment intensification was defined as the receipt of apalutamide, abiraterone acetate, enzalutamide, or chemotherapy (e.g., docetaxel) within 180 days of ADT initiation.

Results

A total of 2515 de novo mCSPC were identified, with 2098 (83%) patients initiating ADT post

SUBMITTER: Gotto GT 

PROVIDER: S-EPMC11790044 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature